Trusted Resource for Clinical Trials, Protocols & Progress
Encryption protects sensitive data in clinical trials, but the real strength lies in how encryption keys are managed. Mismanaged keys can render even the strongest encryption ineffective. Regulatory bodies such as the FDA, EMA, and HIPAA all require not just encryption—but robust, validated key management strategies.
Click to read the full article.
Wearables have transformed clinical trials by enabling real-time monitoring of physiological parameters such as heart rate, sleep patterns, glucose levels, and activity data. From wrist-worn devices to patches and smart garments, these sensors generate vast amounts of electronic source (eSource) data that flow continuously across wireless channels.
Click to read the full article.
Clinical Trial Management Systems (CTMS) are increasingly hosted on cloud infrastructures due to their scalability, remote accessibility, and cost-effectiveness. However, this convenience comes with increased responsibility for securing sensitive trial data, including Protected Health Information (PHI), investigator records, site contracts, and payment histories.
Click to read the full article.
Protected Health Information (PHI) includes any individually identifiable health data collected during clinical trials, such as patient names, medical record numbers, lab results, and treatment history. The Health Insurance Portability and Accountability Act (HIPAA) mandates administrative, technical, and physical safeguards to ensure PHI confidentiality and integrity.
Click to read the full article.
In Electronic Data Capture (EDC) systems, sensitive patient data flows from investigator sites to CROs and sponsors, often via the internet or cloud-based systems. End-to-End Encryption (E2EE) ensures that this data remains confidential and tamper-proof from source to destination.
Click to read the full article.
Clinical trial systems handle sensitive information, including patient health data, investigational product data, protocol deviations, and audit logs. Ensuring this information is protected from unauthorized access or manipulation is a GCP and HIPAA requirement.
Click to read the full article.
Blockchain has the potential to revolutionize clinical trials through transparent data sharing, real-time audit trails, and automated smart contracts. Yet, despite its promise, widescale adoption remains limited in the pharmaceutical industry. Pilot projects rarely graduate to full deployment, and integration across regions or studies is often fragmented.
Click to read the full article.
In clinical trials, the integrity of the Investigational Medicinal Product (IMP) is critical to subject safety, regulatory compliance, and study outcomes. With increasing globalization, trials often rely on complex supply chains involving contract manufacturers, packaging depots, warehouses, and investigator sites across multiple countries.
Click to read the full article.
Clinical trials often involve complex financial relationships between sponsors, CROs, and investigative sites. Payments are typically milestone-based—such as subject screening, visit completion, and database lock—but manual reconciliation often causes delays, disputes, and administrative burden.
Click to read the full article.
